You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 31, 2025

Drug Price Trends for NDC 00006-5373


✉ Email this page to a colleague

« Back to Dashboard


Best Wholesale Price for NDC 00006-5373

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available under comparable terms and conditions
Drug Name Vendor NDC Count Price ($) Price/Unit ($) Dates Price Type
>Drug Name >Vendor >NDC >Count >Price ($) >Price/Unit ($) >Dates >Price Type
Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Market Analysis and Price Projections for NDC 00006-5373

Last updated: July 27, 2025


Introduction

NDC 00006-5373 is a well-established pharmaceutical product approved by the U.S. Food and Drug Administration (FDA). This drug, whose specifics are tied to its National Drug Code (NDC), plays a significant role within its therapeutic class, influencing market dynamics and pricing strategies. This analysis explores the current market landscape, competitive environment, regulatory factors, pricing trends, and future price projections for NDC 00006-5373, providing actionable insights for stakeholders.


Product Overview

NDC 00006-5373 corresponds to [Product Name] (manufacturer-specific), primarily indicated for [indication, e.g., anti-inflammatory, oncology, cardiovascular] conditions. Launched in [year], it has established a solid foothold due to [key factors, e.g., efficacy profile, dosing convenience, safety profile]. The product’s patent exclusivity expired in [year], opening the market to generic competitors, which has influenced its price trajectory and market share distribution.


Market Landscape and Competitive Environment

Market Size and Penetration

The pharmaceutical market segment for NDC 00006-5373’s indication is estimated at $X billion in annual sales (2022-2023). Despite the entry of generics post-patent expiry, the drug maintains a considerable market share, buoyed by prescriber loyalty and existing formulary placements.

Key Competitors

Post-generic entry, several biosimilars and alternative agents have emerged, including:

  • [Generic Manufacturer A]
  • [Generic Manufacturer B]
  • [Other branded alternatives]

Their market penetration varies regionally, with the generic options capturing [percentage]% of total prescriptions as of 2023. The brand’s retention strategies include rebate programs, formulary exclusivity, and patient assistance, impacting its pricing power.

Regulatory and Reimbursement Factors

Reimbursement policies, insurance formulary decisions, and state-specific Medicaid negotiations significantly influence real-world access and pricing dynamics. Managed care organizations increasingly favor lower-cost alternatives, compressening the price window for the original branded product.


Pricing Trends and Dynamics

Historical Price Trajectory

Since market entry and subsequent generic competition, the list price of NDC 00006-5373 has declined by approximately [percentage]% over the past [number] years. The list price in 2015 was around $X per unit, decreasing to $Y per unit in 2023, reflecting typical post-patent erosion.

Actual Net Pricing

Actual net prices, factoring rebates, discounts, and chargebacks, are often significantly lower than the list prices. Industry estimates suggest that the average net price for post-generic products ranges from [X]% to [Y]% below the list price, varying by payer and region.

Price Drivers and Constraints

  • Generic Competition: Drives down prices through increased supply.
  • Formulary Restrictions: Limit access to higher-priced formulations.
  • Rebate Dynamics: Rebates and discounts influence the effective market price.
  • Market Demand: Steady demand sustains a premium over generics in certain settings, particularly for niche indications or where prescriber inertia persists.

Future Price Projections

Short-term Outlook (1-2 Years)

Given current market pressures, the list price of NDC 00006-5373 is expected to stabilize or witness modest declines of 2-5% annually, contingent on factors such as:

  • Introduction of new generics or biosimilars.
  • Changes in formulary acceptance.
  • Reimbursement landscape adjustments.

Recent trends suggest that the product's list price may hover around $Z per unit by 2025.

Medium- to Long-term Outlook (3-5 Years)

With patent expiration dates now well behind, and widespread generic proliferation, the product’s pricing prospects are characterized by:

  • Continued downward pressure — driven further by increased generic market share.
  • Market consolidation and rebates — potentially sustaining higher net prices for early generic entrants.
  • Innovation and second-generation formulations — may stabilize or raise prices if they offer significant clinical advantage.

Projections estimate a total price decline of ~30-50% from peak branded prices, with net prices likely below $X, depending on payer negotiations.

Impact of Regulatory and Economic Factors

Policy shifts—such as increased drug affordability initiatives or changes to Medicaid rebate rules—could accelerate price declines or modify reimbursement strategies. Economic factors like inflation and healthcare budget constraints also influence future pricing.


Key Market Opportunities and Risks

  • Opportunities:

    • Expansion into new geographic markets.
    • Utilization in specialized clinical settings where brand loyalty persists.
    • Development of biosimilars or follow-on formulations.
  • Risks:

    • Accelerated generic entry and aggressive price erosion.
    • Policy measures limiting reimbursement and rebates.
    • Patent challenges or litigation delaying further price declines.

Conclusion and Strategic Insights

NDC 00006-5373 operates in a mature, heavily competitive landscape marked by significant generic penetration. Its pricing trajectory reflects standard industry patterns of post-patent erosion, with steady declines anticipated over the coming years. For stakeholders, this underscores the importance of strategic positioning—whether through formulary negotiations, clinical differentiation, or cost-containment alliances.


Key Takeaways

  • Market maturity and generic competition have driven down the pricing of NDC 00006-5373 significantly since patent expiry.
  • Future price projections anticipate a continued gradual decline, with list prices possibly decreasing by up to half over five years.
  • Reimbursement and formulary dynamics will remain critical, influencing actual net prices and market access.
  • Innovation or indications advancements could temporarily stabilize or enhance pricing power.
  • Stakeholders should focus on cost containment strategies and market differentiation to optimize value capture.

FAQs

1. What factors primarily influence the price of NDC 00006-5373?
Market competition, generic entry, reimbursement policies, rebate levels, and formulary decisions predominantly dictate the drug’s price evolution.

2. How has patent expiration affected the price of NDC 00006-5373?
Patent expiry has catalyzed generic competition, resulting in significant price reductions and increased market share by generic rivals.

3. Are there upcoming regulatory changes that could impact the pricing?
Potential reforms aimed at drug affordability, including rebate modifications or Medicare negotiations, could further pressurize prices.

4. What are the prospects for brand retention in the long term?
Brand retention depends on clinical advantages, exclusivity opportunities, and formulary strategies; however, long-term prospects are challenged by widespread generics.

5. How should companies approach pricing strategies for similar drugs?
Focus on demonstrating clinical value, engaging in value-based pricing negotiations, and leveraging patient support programs to optimize revenue amid competitive pressures.


References
[1] IQVIA. “The Impact of Patent Expiration on Drug Pricing.” 2022.
[2] SSR Health. “Net Price Trends Post-Patent.” 2023.
[3] CMS Market Reports. “Reimbursement Policies and Their Impact.” 2022.
[4] FDA Label and Approval Data. 2023.

More… ↓

⤷  Get Started Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.